Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06137690
Other study ID # LJzhou
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 1, 2018
Est. completion date March 1, 2024

Study information

Verified date February 2024
Source People's Hospital of Zhengzhou University
Contact Zhou Li-juan Zhou Li-juan, master
Phone 13838014946
Email zhou750423@126.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This was a prospective clinical study that all voriconazole-treated adult Chinese patients with invasive pulmonary infection admitted to Zhengzhou Central Hospital affiliated to Zhengzhou University from July 2018 to June 2023. The initial voriconazole serum trough concentration, Correlation of various factors, and risk prediction factors for voriconazole serum trough concentration and hepatotoxicity were compared between elderly and non-elderly patients.


Description:

A prospective observational study was conducted from July 2018 to June 2023 in Zhengzhou Central Hospital Affiliated to Zhengzhou University. This study was carried out in accordance with the following criteria: (1) patients who met the criteria for diagnosis of IFI, (2) age ≥ 18 years, (3) The duration of VCZ treatment course ≥ 7 days. Patients were excluded who fulfilled any of the following criteria: (1) Patients who allergic to VCZ, (2) use other anti-fungal drugs during the use of VCZ, (3) do not qualify for blood sampling monitored by blood concentration, (4) pregnant or lactating women, (5) patients who haven't completely and accurately efficacy and safety data, (6) patients who are treated with a combination of liver enzyme inducers and inhibitors (carbamazepine, phenobarbital, phenytoin, cimetidine, rifampin, rifapentine, rifabutin, and so on),(7) patients who are treated with a combination of Paxlovid or Azvudine. Grouping: Patients were divided into the elderly group (group A, ≥ 60 years) and the non-elderly group (group B, < 60 years) according to ages. All the recruited patients were treated with voriconazole. Voriconazole was intravenously administered 2 times at the loading dose of 6 mg/Kg or orally administered 2 times at the loading dose of 400mg at 12h intervals, followed by a maintenance dose of 4 mg/Kg or 200 mg at 12 h intervals.


Recruitment information / eligibility

Status Recruiting
Enrollment 550
Est. completion date March 1, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 98 Years
Eligibility Inclusion Criteria: - patients who met the criteria for diagnosis of IFI - age = 18 years - The duration of VCZ treatment course = 7 days. Exclusion Criteria: - Patients who allergic to VCZ - use other anti-fungal drugs during the use of VCZ - do not qualify for blood sampling monitored by blood concentration - pregnant or lactating women - patients who haven't completely and accurately efficacy and safety data - patients who are treated with a combination of liver enzyme inducers and inhibitors(carbamazepine, phenobarbital, phenytoin, cimetidine, rifampin, rifapentine, rifabutin, and so on) - patients who are treated with a combination of Paxlovid or Azvudine.

Study Design


Intervention

Device:
other antifungal agents,breathing machine
If treatment failure for patients in group A and group B,change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.

Locations

Country Name City State
China Zhengzhou Central Hospital affiliated to Zhengzhou University Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
People's Hospital of Zhengzhou University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum voriconazole trough concentrations If all patients were administrated by loading dose, voriconazole trough samples were taken immediately 30 minutes before voriconazole administration on the Third day. If all patients were not administrated by loading dose, voriconazole trough samples were taken immediately 30 minutes before voriconazole administration on the sixth day. Blood samples for 2-3 mL were collected in blood-collection tubes without any additives and centrifuged at 3500 rpm for 10min. Serum trough concentrations were determined by a high-performance liquid chromatography method as previously described. A initial steady-state trough concentration blood sample was obtained before dose adjustment for all patients. Each patient received at least one steady-state blood sample. The detections were completed in Translational Medicine Center of Zhengzhou Central Hospital affiliated to Zhengzhou University. 0.5 hour before voriconazole administration on the Third or sixth day.
Primary CYP2C19 Genotyping CYP2C19 genotype was determined from peripheral blood, which was extracted and stored in an EDTA anticoagulant tube. Real-time fluorescence quantitative PCR (ThermoFisher Applied Biosystems 7500 fast PCR) was performed using a Human CYP2C19 gene detection kit (PCR-fluorescence probe method, Wuhan YZY Medical Science and Technology Co., Ltd, China) following the manufacturer's instructions. Genomic DNA was isolated from whole blood using QIAamp DNA blood kits (Qiagen, Hilden, Germany). According to nomenclature by the Clinical Pharmacogenetics Implementation Consortium (CPIC®), the CYP2C19 genotype was classified as ultrarapid metabolizer (*17/*17), rapid metabolizer (*1/*17), normal metabolizer (*1/*1), intermediate metabolizer (*1/*2, *1/*3, *2/*17, *3/*17), or poor metabolizer (*2/*2, *2/*3, *3/*3). Unlimited blood drawing time.
Primary The difference of average voriconazole serum trough concentration between group A and group B The differences were counted between group A and group B by measuring each patient's voriconazole serum trough concentration. From July 2018 to June 2023
Primary Analysis of factors affecting voriconazole serum trough concentration A multiple linear stepwise regression analysis was performed by using voriconazole serum trough concentration (Y) as the dependent variable, and sex (x1), age (x2), body weight (x3), VCZ route of administration (x4), CYP2C19 phenotype (x5), the average daily dose (x6), PPIs (x7), methylprednisolone (x8), CRP (x9) , PCT (x10), IL-6 (x11), Albumin (x12), ALP (x13), and TBIL (x14) as independent variables. Linear regression analysis reveals the regression equation and independent risk factors affecting voriconazole serum trough concentration. From July 2018 to June 2023
Secondary C-reaction protein (CRP) It was completed before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy in Zhengzhou city clinical inspection center. Before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy
Secondary Alanine aminotransferase (ALT) It was completed before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy in Zhengzhou city clinical inspection center. Before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy
Secondary Aspartatrtransaminase (AST) It was completed before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy in Zhengzhou city clinical inspection center. Before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy
Secondary Gamma-glutamyl transferase(GGT) It was completed before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy in Zhengzhou city clinical inspection center. Before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy
Secondary Alkaline phosphatase (ALP) It was completed before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy in Zhengzhou city clinical inspection center. Before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy
Secondary Total bilirubin (TBIL) It was completed before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy in Zhengzhou city clinical inspection center. Before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy
Secondary procalcitonin(PCT) It was completed before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy in Zhengzhou city clinical inspection center. Before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy
Secondary interleukin- 6(IL-6) It was completed before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy in Zhengzhou city clinical inspection center. before initiation, On the day of blood sample extraction with serum trough concentration, and completion of voriconazole therapy
See also
  Status Clinical Trial Phase
Completed NCT01888458 - Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD) Phase 2
Completed NCT00412893 - Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Phase 3
Completed NCT03066011 - Registry of Patients Treated With Systemic Mold-Active Triazoles
Completed NCT04004078 - An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
Completed NCT01576653 - Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL N/A
Enrolling by invitation NCT02510053 - Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit N/A
Completed NCT01198236 - Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Phase 4
Completed NCT01783379 - Pharmacokinetics of Micafungin in Patients Intensive Care Unit
Completed NCT01533558 - Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
Recruiting NCT03149562 - Association of Plasma Transfusions and Invasive Fungal Infection
Recruiting NCT04665037 - Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) Phase 2
Terminated NCT01148160 - Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy N/A
Withdrawn NCT01185405 - Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients N/A
Completed NCT00893555 - Pharmacologic Optimization of Voriconazole Phase 3
Unknown status NCT00460330 - Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT N/A
Completed NCT02823132 - Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia N/A